1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs is sponsored by Various Federal Agencies (e.g., NIH). Congressionally mandated programs to ensure small businesses are included in federal spending on innovation and research. These grants are primarily for for-profit small businesses to develop innovative projects, often with an emphasis on commercialization.
For example, NIH offers STTR grants to develop serious STEM games with a focus on biology that addresses health and medicine questions.
Get alerted about grants like this
Get emailed when new opportunities from “Various Federal Agencies (e.g., NIH)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: U.S.-based small businesses with fewer than 500 employees. Specific eligibility may vary by agency and solicitation. Confirm the full requirements in the official notice before applying.
The current listing shows varies by agency and phase (e.g., Phase 1 can be around $100,000). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs is funded by Various Federal Agencies (e.g., NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Past winners and funding trends for this program
NIH's FY2026 budget held steady at $47.2 billion — yet by the end of February the agency had issued roughly 66% fewer competitive grant awards than its FY21–24 average, and by late spring award volume was still running dramatically below historical norms. The cause is not a budget cut. It is a pipeline failure: only 14 Notices of Funding Opportunity published by mid-March versus 756 in all of 2024, a workforce down nearly 20%, funds held by OMB into March, and new political-appointee sign-off on NOFOs. FY25 success rates fell to 17% — the lowest in 30 years — and early-stage investigators dropped to 18.5%. This is the definitive breakdown of what is happening, why the money isn't moving, and the concrete diversification strategy labs need for the next 18 months.
Read articleAfter an authorization lapse froze new SBIR/STTR awards for five months, NIH reopens its submission window on August 5, 2026, with a first standard deadline of September 8. Phase I awards run to $323,090, Phase II to $2,153,927, with published waiver topics reaching $700,000 and $3 million — and a new Phase IIB Strategic Breakthrough lane up to $30 million. Here is how the restarted omnibus is structured, why applying early matters more than usual this cycle, and how to position a life-science startup to win.
Read articleNIH has awarded 74% fewer new grants than its 2021-2024 average and is roughly $1 billion behind its normal timeline, but the FY2026 money still has to go out the door before the fiscal year ends. Here is why a year-end obligation cliff is coming, who is positioned to catch it, and how applicants should prepare for a compressed Q4 award rush.
Read article